Receptor of Advanced Glycated End Products Gene Polymorphism in Patients with Rheumatoid Arthritis

Document Type : Original Article

Authors

1 Clinical Pathology Department, Faculty of Medicine, Zagazig University

2 Rheumatology and rehabilitation Department, Faculty of Medicine, Zagazig University

Abstract

Background: Through its capacity to intensify inflammatory pathways, Rheumatoid arthritis (RA) has been connected to the receptor for advanced glycation end products (RAGE). So, in those with rheumatoid arthritis, the RAGE gene polymorphism may be a significant indicator of disease activity.

Aim: Illustration of the role of RAGE gene polymorphism (G82S) in susceptibility of rheumatoid arthritis.

Subjects and methods: Thirty individuals were used in this case control study, which was conducted at the Zagazig University hospitals' Clinical Pathology, Rheumatology, and Rehabilitation departments after obtaining their written agreement for ethical reasons. The participants were split up into two groups: fifteen RA cases and fifteen healthy volunteers who acted as the control group. A molecular investigation of the RAGE gene's glycine-to-serine (G82S) polymorphism was done for genotyping.

Results: Rheumatoid arthritis patients have allele G levels that are 7 times greater than those in the control group, with a 95% CI of 1.38 to 35.5. Significant difference: p=0.009.

Conclusion: The RAGE gene polymorphism (G82S) with allele G were higher in rheumatoid arthritis patients than the control group. Sadly, we were unable to discover a link between gene variation and disease activity.

Keywords

Main Subjects

Zagazig University Medical Journal
Volume 30, Issue 1.3
March and April 2024
Pages 207-214

Files

Share

How to cite

Statistics